ALPHA-1,3-GALACTOSYLTRANSFERASE DEFICIENT PIGS

ALPHA-1,3-半乳糖基转移酶缺陷猪

• 批准号: 6658864
• 负责人: Robert J Hawley
• 金额: $ 4.5万
• 依托单位: BIOTRANSPLANT, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-03-01 至 2003-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6658864
• 关键词: biotechnology; embryo /fetus culture; enzyme deficiency; fibroblasts; galactosyltransferases; gene expression; gene targeting; genetically modified animals; molecular cloning; nuclear transfer; swine; technology /technique development; tissue /cell culture; transplant rejection; xenotransplantation

DESCRIPTION: (Scanned from the Applicant's Description): Improvements in clinical management of immune rejection following organ transplantation have resulted in a steadily increasing demand for donor organs. Unfortunately, efforts to increase the supply of human organs available for transplantation have failed to keep pace with demand and appear unlikely to do so. Considerable research and development efforts have been devoted toward the use of animal organs, specifically those from pigs, as an innovative alternative to human organs. However, a number of xenotransplantation barriers need to be overcome prior to clinical use of pig organs. Genetic engineering of donor pigs, including generation of pigs with gene targeted modifications, will be necessary to overcome these barriers. A Phase II program is proposed to modify pigs for use in xenotransplantation, using homologous recombination to create both genetic knock-outs and knock-ins. Nuclear transfer technology, using donor fibroblast lines carrying the desired genetic modifications, will be used to generate the desired founder animals. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（从申请人的描述中扫描）： 器官移植后免疫排斥反应的临床处理 导致对捐赠器官的需求稳步增长。不幸的是， 努力增加可供移植的人体器官的供应 未能跟上需求的步伐，而且似乎不太可能这样做。相当大 研究和开发工作一直致力于利用动物 器官，特别是来自猪的器官，作为人类的创新替代品， 机关然而，需要克服一些异种移植障碍 在猪器官的临床应用之前。供体猪的基因工程， 包括通过基因靶向修饰产生猪， 必须克服这些障碍。第二阶段计划建议修改 用于异种移植的猪，使用同源重组来产生 基因敲除和基因敲入。核移植技术，使用供体 携带所需遗传修饰的成纤维细胞系将用于 产生所需的创始动物。 拟议商业应用：不可用